These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

637 related articles for article (PubMed ID: 32495109)

  • 1. Mutation Status and Prognostic Value of KRAS and BRAF in Southeast Iranian Colorectal Cancer Patients: First Report from Southeast of Iran.
    Yari A; Samoudi A; Afzali A; Karam ZM; Karimaldini NK; Abadi MFS; Ziasistani M; Zangouey MR; Dabiri S
    J Gastrointest Cancer; 2021 Jun; 52(2):557-568. PubMed ID: 32495109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of BRAF and KRAS Mutation in Relation to Colorectal Cancer Survival in Iranian Patients: Correlated to Microsatellite Instability.
    Nazemalhosseini-Mojarad E; Kishani Farahani R; Mehrizi M; Baghaei K; Yaghoob Taleghani M; Golmohammadi M; Peyravian N; Ashtari S; Pourhoseingholi MA; Asadzadeh Aghdaei H; Zali MR
    J Gastrointest Cancer; 2020 Mar; 51(1):53-62. PubMed ID: 30635874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS, NRAS, BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients.
    Mirzapoor Abbasabadi Z; Hamedi Asl D; Rahmani B; Shahbadori R; Karami S; Peymani A; Taghizadeh S; Samiee Rad F
    J Clin Lab Anal; 2023 Mar; 37(5):e24868. PubMed ID: 36930789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological Features and Prognostic Value of KRAS/NRAS/BRAF Mutations in Colorectal Cancer Patients of Central China.
    Chang XN; Shang FM; Jiang HY; Chen C; Zhao ZY; Deng SH; Fan J; Dong XC; Yang M; Li Y; Cai KL; Liu L; Liu HL; Nie X
    Curr Med Sci; 2021 Feb; 41(1):118-126. PubMed ID: 33582915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.
    Ye JX; Liu Y; Qin Y; Zhong HH; Yi WN; Shi XY
    World J Gastroenterol; 2015 Feb; 21(5):1595-605. PubMed ID: 25663779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
    Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
    Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation Analysis of KRAS and BRAF Genes in Metastatic Colorectal Cancer: a First Large Scale Study from Iran.
    Koochak A; Rakhshani N; Karbalaie Niya MH; Tameshkel FS; Sohrabi MR; Babaee MR; Rezvani H; Bahar B; Imanzade F; Zamani F; Khonsari MR; Ajdarkosh H; Hemmasi G
    Asian Pac J Cancer Prev; 2016; 17(2):603-8. PubMed ID: 26925650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
    de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
    Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan.
    Ikoma T; Shimokawa M; Kotaka M; Matsumoto T; Nagai H; Boku S; Shibata N; Yasui H; Satake H
    BMC Cancer; 2021 May; 21(1):518. PubMed ID: 33962575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer.
    Kadowaki S; Kakuta M; Takahashi S; Takahashi A; Arai Y; Nishimura Y; Yatsuoka T; Ooki A; Yamaguchi K; Matsuo K; Muro K; Akagi K
    World J Gastroenterol; 2015 Jan; 21(4):1275-83. PubMed ID: 25632202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
    Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
    JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
    Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
    PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases.
    Brunsell TH; Sveen A; Bjørnbeth BA; Røsok BI; Danielsen SA; Brudvik KW; Berg KCG; Johannessen B; Cengija V; Abildgaard A; Guren MG; Nesbakken A; Lothe RA
    Clin Colorectal Cancer; 2020 Mar; 19(1):e26-e47. PubMed ID: 31982351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival.
    Olevian DC; Nikiforova MN; Chiosea S; Sun W; Bahary N; Kuan SF; Pai RK
    Hum Pathol; 2016 Mar; 49():124-34. PubMed ID: 26826419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma.
    Jun SY; Kim M; Jin Gu M; Kyung Bae Y; Chang HK; Sun Jung E; Jang KT; Kim J; Yu E; Woon Eom D; Hong SM
    Mod Pathol; 2016 Apr; 29(4):402-15. PubMed ID: 26892442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.
    Cushman-Vokoun AM; Stover DG; Zhao Z; Koehler EA; Berlin JD; Vnencak-Jones CL
    Clin Colorectal Cancer; 2013 Sep; 12(3):168-78. PubMed ID: 23773459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between molecular subtypes of colorectal cancer and patient survival.
    Phipps AI; Limburg PJ; Baron JA; Burnett-Hartman AN; Weisenberger DJ; Laird PW; Sinicrope FA; Rosty C; Buchanan DD; Potter JD; Newcomb PA
    Gastroenterology; 2015 Jan; 148(1):77-87.e2. PubMed ID: 25280443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.
    Chen J; Guo F; Shi X; Zhang L; Zhang A; Jin H; He Y
    BMC Cancer; 2014 Nov; 14():802. PubMed ID: 25367198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
    Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
    J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.